Prediction of sepsis mortality using metabolite biomarkers in the blood: a meta-analysis of death-related pathways and prospective validation
Abstract Background Sepsis is a leading cause of death in intensive care units (ICUs), but outcomes of individual patients are difficult to predict. The recently developed clinical metabolomics has been recognized as a promising tool in the clinical practice of critical illness. The objective of thi...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-04-01
|
| Series: | BMC Medicine |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12916-020-01546-5 |
| _version_ | 1831524328136507392 |
|---|---|
| author | Jing Wang Yizhu Sun Shengnan Teng Kefeng Li |
| author_facet | Jing Wang Yizhu Sun Shengnan Teng Kefeng Li |
| author_sort | Jing Wang |
| collection | DOAJ |
| description | Abstract Background Sepsis is a leading cause of death in intensive care units (ICUs), but outcomes of individual patients are difficult to predict. The recently developed clinical metabolomics has been recognized as a promising tool in the clinical practice of critical illness. The objective of this study was to identify the unique metabolic biomarkers and their pathways in the blood of sepsis nonsurvivors and to assess the prognostic value of these pathways. Methods We searched PubMed, EMBASE, Cochrane, Web of Science, CNKI, Wangfang Data, and CQVIP from inception until July 2019. Eligible studies included the metabolomic analysis of blood samples from sepsis patients with the outcome. The metabolic pathway was assigned to each metabolite biomarker. The meta-analysis was performed using the pooled fold changes, area under the receiver operating characteristic curve (AUROC), and vote-counting of metabolic pathways. We also conducted a prospective cohort metabolomic study to validate the findings of our meta-analysis. Results The meta-analysis included 21 cohorts reported in 16 studies with 2509 metabolite comparisons in the blood of 1287 individuals. We found highly limited overlap of the reported metabolite biomarkers across studies. However, these metabolites were enriched in several death-related metabolic pathways (DRMPs) including amino acids, mitochondrial metabolism, eicosanoids, and lysophospholipids. Prediction of sepsis death using DRMPs yielded a pooled AUROC of 0.81 (95% CI 0.76–0.87), which was similar to the combined metabolite biomarkers with a merged AUROC of 0.82 (95% CI 0.78–0.86) (P > 0.05). A prospective metabolomic analysis of 188 sepsis patients (134 survivors and 54 nonsurvivors) using the metabolites from DRMPs produced an AUROC of 0.88 (95% CI 0.78–0.97). The sensitivity and specificity for the prediction of sepsis death were 80.4% (95% CI 66.9–89.4%) and 78.8% (95% CI 62.3–89.3%), respectively. Conclusions DRMP analysis minimizes the discrepancies of results obtained from different metabolomic methods and is more practical than blood metabolite biomarkers for sepsis mortality prediction. Trial registration The meta-analysis was registered on OSF Registries , and the prospective cohort study was registered on the Chinese Clinical Trial Registry ( ChiCTR1800015321 ). |
| first_indexed | 2024-12-16T09:00:16Z |
| format | Article |
| id | doaj.art-98a0a6bf9a974f938c776762e75d678a |
| institution | Directory Open Access Journal |
| issn | 1741-7015 |
| language | English |
| last_indexed | 2024-12-16T09:00:16Z |
| publishDate | 2020-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Medicine |
| spelling | doaj.art-98a0a6bf9a974f938c776762e75d678a2022-12-21T22:37:11ZengBMCBMC Medicine1741-70152020-04-0118111510.1186/s12916-020-01546-5Prediction of sepsis mortality using metabolite biomarkers in the blood: a meta-analysis of death-related pathways and prospective validationJing Wang0Yizhu Sun1Shengnan Teng2Kefeng Li3Department of Critical Care Medicine, Yantai Yuhuangding HospitalDepartment of Critical Care Medicine, Yantai Yuhuangding HospitalDepartment of Critical Care Medicine, Yantai Yuhuangding HospitalSchool of Medicine, University of CaliforniaAbstract Background Sepsis is a leading cause of death in intensive care units (ICUs), but outcomes of individual patients are difficult to predict. The recently developed clinical metabolomics has been recognized as a promising tool in the clinical practice of critical illness. The objective of this study was to identify the unique metabolic biomarkers and their pathways in the blood of sepsis nonsurvivors and to assess the prognostic value of these pathways. Methods We searched PubMed, EMBASE, Cochrane, Web of Science, CNKI, Wangfang Data, and CQVIP from inception until July 2019. Eligible studies included the metabolomic analysis of blood samples from sepsis patients with the outcome. The metabolic pathway was assigned to each metabolite biomarker. The meta-analysis was performed using the pooled fold changes, area under the receiver operating characteristic curve (AUROC), and vote-counting of metabolic pathways. We also conducted a prospective cohort metabolomic study to validate the findings of our meta-analysis. Results The meta-analysis included 21 cohorts reported in 16 studies with 2509 metabolite comparisons in the blood of 1287 individuals. We found highly limited overlap of the reported metabolite biomarkers across studies. However, these metabolites were enriched in several death-related metabolic pathways (DRMPs) including amino acids, mitochondrial metabolism, eicosanoids, and lysophospholipids. Prediction of sepsis death using DRMPs yielded a pooled AUROC of 0.81 (95% CI 0.76–0.87), which was similar to the combined metabolite biomarkers with a merged AUROC of 0.82 (95% CI 0.78–0.86) (P > 0.05). A prospective metabolomic analysis of 188 sepsis patients (134 survivors and 54 nonsurvivors) using the metabolites from DRMPs produced an AUROC of 0.88 (95% CI 0.78–0.97). The sensitivity and specificity for the prediction of sepsis death were 80.4% (95% CI 66.9–89.4%) and 78.8% (95% CI 62.3–89.3%), respectively. Conclusions DRMP analysis minimizes the discrepancies of results obtained from different metabolomic methods and is more practical than blood metabolite biomarkers for sepsis mortality prediction. Trial registration The meta-analysis was registered on OSF Registries , and the prospective cohort study was registered on the Chinese Clinical Trial Registry ( ChiCTR1800015321 ).http://link.springer.com/article/10.1186/s12916-020-01546-5SepsisMetabolomicsBloodPredictionOutcomeDeath-related metabolic pathways |
| spellingShingle | Jing Wang Yizhu Sun Shengnan Teng Kefeng Li Prediction of sepsis mortality using metabolite biomarkers in the blood: a meta-analysis of death-related pathways and prospective validation BMC Medicine Sepsis Metabolomics Blood Prediction Outcome Death-related metabolic pathways |
| title | Prediction of sepsis mortality using metabolite biomarkers in the blood: a meta-analysis of death-related pathways and prospective validation |
| title_full | Prediction of sepsis mortality using metabolite biomarkers in the blood: a meta-analysis of death-related pathways and prospective validation |
| title_fullStr | Prediction of sepsis mortality using metabolite biomarkers in the blood: a meta-analysis of death-related pathways and prospective validation |
| title_full_unstemmed | Prediction of sepsis mortality using metabolite biomarkers in the blood: a meta-analysis of death-related pathways and prospective validation |
| title_short | Prediction of sepsis mortality using metabolite biomarkers in the blood: a meta-analysis of death-related pathways and prospective validation |
| title_sort | prediction of sepsis mortality using metabolite biomarkers in the blood a meta analysis of death related pathways and prospective validation |
| topic | Sepsis Metabolomics Blood Prediction Outcome Death-related metabolic pathways |
| url | http://link.springer.com/article/10.1186/s12916-020-01546-5 |
| work_keys_str_mv | AT jingwang predictionofsepsismortalityusingmetabolitebiomarkersinthebloodametaanalysisofdeathrelatedpathwaysandprospectivevalidation AT yizhusun predictionofsepsismortalityusingmetabolitebiomarkersinthebloodametaanalysisofdeathrelatedpathwaysandprospectivevalidation AT shengnanteng predictionofsepsismortalityusingmetabolitebiomarkersinthebloodametaanalysisofdeathrelatedpathwaysandprospectivevalidation AT kefengli predictionofsepsismortalityusingmetabolitebiomarkersinthebloodametaanalysisofdeathrelatedpathwaysandprospectivevalidation |